NRXS רווחיות מכירות גולמית NeurAxis Inc.

NeurAxis, Inc. (NRXS) is implementing eco-friendly production standards while protecting its market share with an FDA-approved neurostimulation method. The gross profit margin reflects profitability dynamics, where the 86.20 mark characterizes this parameter. The company has achieved a breakthrough in non-invasive therapy by creating a wearable device to alleviate pediatric abdominal pain without the use of medication.
פילוחים אנליטיים ודוחות נתונים של חברת NeurAxis, Inc. (NRXS)

Demand for NeurAxis, Inc. (NRXS) neurostimulation systems remains stable due to the critical necessity of pain therapy, establishing a foundation for high operational efficiency. The gross margin history reflects the profit share after deducting direct production costs, allowing investors to assess the business's ability to convert revenue into capital and maintain sustainable market value within the defensive medtech sector.